Forte Biosciences, Inc.
FBRX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for FBRX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · FBRX
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company developing FB102, a product candidate for autoimmune and autoimmune-related indications, currently in Phase 1b and Phase 2 clinical trials.
Key risk: Dependence on FB102
BioSniper Score
Based on 5 of 6 signals
Market Cap
$1.63B
Cash Runway
25.4 moLead Asset
fb-102 (Phase 2)
Next Catalyst
Phase2_Topline · Dec 31, 2026Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 4 clinical trials · 1 catalyst for Forte Biosciences, Inc..
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company developing FB102, a product candidate for autoimmune and autoimmune-related indications, currently in Phase 1b and Phase 2 clinical trials.
- Forte is a clinical-stage biopharmaceutical company focused on developing FB102 for autoimmune indications such as celiac disease, vitiligo, alopecia areata, and type 1 diabetes [sec_mda · as of 2026-08-12].
- FB102 is currently in clinical development in two Phase 1b and one Phase 2 clinical trials [sec_mda · as of 2026-08-12].
- As of June 30, 2026, Forte had cash and cash equivalents of $49.6 million [sec].
- Forte has no approved products and has not generated any revenue from product sales [sec_mda · as of 2026-03-31].
- The company completed a public offering in April 2026, raising gross proceeds of $172.5 million [sec_mda · as of 2026-05-11].
What works
- Forte has a potentially broad application for FB102 across multiple autoimmune indications, including celiac disease, vitiligo, alopecia areata, and type 1 diabetes [sec_mda · as of 2026-08-12].
- The company raised significant capital through a public offering in April 2026, with net proceeds of $162.1 million, providing financial resources for ongoing development [sec_mda · as of 2026-05-11].
- Forte believes its current cash and cash equivalents will fund operations for at least twelve months from the issuance date of its most recent Form 10-K [sec_mda · as of 2026-03-31].
What to weigh
- Forte's business is almost entirely dependent on the success of FB102, which may not be successful [sec_mda · as of 2026-03-31].
- The company has no approved products and has not generated any revenue from product sales or out-licensing [sec_mda · as of 2026-03-31].
- Forte will require significant additional capital to complete clinical development of FB102, and its future capital requirements are difficult to forecast [sec_mda · as of 2026-08-12].
- Early clinical trial results may not predict future success, and the company faces risks of negative or inconclusive clinical data [sec_mda · as of 2026-03-31].
From the filings
Quoted directly from source documents.
FB102 is being developed for multiple autoimmune indications
“broad application for autoimmune and autoimmune-related indications such as celiac disease, vitiligo, alopecia areata and type 1 diabetes”
SEC MD&A · August 12, 2026
Forte has no approved products and limited operating history
“Forte has no products approved for commercial sale and has not generated any revenue from product sales”
SEC MD&A · March 31, 2026
Forte raised $172.5 million in gross proceeds from a 2026 offering
“The gross proceeds from the 2026 Offering were $172.5 million including the exercise of the underwriters' option”
SEC MD&A · May 11, 2026
Catalyst timeline
- 2026-12-31 · Phase2_Topline · fb102 — Phase 2 Readout: fb102 — Topline data from the Phase 2 trial of FB102 is expected, which will be a key indicator of the product candidate's efficacy and safety.
Risks & what to watch (4)›
Key risks
- Dependence on FB102 — Forte's business is almost entirely dependent on the success of FB102, which may not be successful [sec_mda · as of 2026-03-31].
- Need for additional capital — Forte will require significant additional capital to complete clinical development of FB102 [sec_mda · as of 2026-08-12].
- No revenue or approved products — Forte has no approved products and has not generated any revenue from product sales [sec_mda · as of 2026-03-31].
- Clinical trial uncertainty — Early clinical trial results may not predict future success, and trials may produce negative or inconclusive results [sec_mda · as of 2026-03-31].
What to watch
- Phase 2 topline data for FB102 expected around December 31, 2026 [catalyst].
- Initiation and progress of additional clinical trials for FB102 [sec_mda · as of 2026-08-12].
- Any strategic alliances, licensing, or other arrangements that may be established [sec_mda · as of 2026-08-12].
- Regulatory developments and outcomes from ongoing clinical studies [sec_mda · as of 2026-03-31].
Sources: Catalysts · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Forte Biosciences, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Forte Biosciences, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
25.4 months
D/E 0.12
Lead: Phase 2
2 candidates
1 upcoming, next in ~123d
No insider transactions in the last 180 days
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
68
Total value held
$393.3M
| Holder | Shares | Value |
|---|---|---|
| janus henderson group plc | 2,376,120 | $61.6M |
| federated hermes, inc. | 1,765,516 | $45.7M |
| fred alger management, llc | 1,273,965 | $33.0M |
| orbimed advisors llc | 1,196,955 | $31.0M |
| vanguard capital management llc | 1,063,384 | $27.5M |
| affinity asset advisors, llc | 1,011,890 | $26.2M |
| mpm bioimpact llc | 1,000,682 | $25.9M |
| adage capital partners gp, l.l.c. | 950,000 | $24.6M |
| woodline partners lp | 663,974 | $17.2M |
| morgan stanley | 500,298 | $13.0M |
Showing top 10 of 68 institutional holders of Forte Biosciences, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 4.8%
- Days to cover
- 2.1
- Shares short
- 843,652
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
FBRX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Forte Biosciences, Inc.?
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company developing FB102, a product candidate for autoimmune and autoimmune-related indications, currently in Phase 1b and Phase 2 clinical trials.
What is Forte Biosciences, Inc.'s lead drug candidate?
Forte Biosciences, Inc.'s most advanced tracked candidate is fb-102 (Phase 2) for Alopecia Areata; Vitiligo; Celiac Disease.
What is Forte Biosciences, Inc.'s next catalyst?
Forte Biosciences, Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: fb102" — expected December 31, 2026.
Who is the CEO of Forte Biosciences, Inc.?
Dr. Paul A. Wagner Ph.D. is the chief executive officer of Forte Biosciences, Inc. (FBRX).
Where is Forte Biosciences, Inc. headquartered?
Forte Biosciences, Inc. (FBRX) is headquartered in Dallas, TX, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.